Dataset
Dataset: covid-19_results_mar_dec_2020.zip, 1.22 GB
Access Condition: Open access

Documentation: efficacy_of_fda_approved_hiv_drugs_on_sars-cov-2.txt, 720 bytes
Access Condition: Open access
Description:
Methodology description (English)

Institutional repository: Fulir DATA

Cite this document

Tomić, D. (2021). Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein [Data set]. https://urn.nsk.hr/urn:nbn:hr:241:733364.

Tomić, Draško. Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein. Institut Ruđer Bošković, 2021. 17 Jul 2024. https://urn.nsk.hr/urn:nbn:hr:241:733364.

Tomić, Draško. 2021. Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein. Institut Ruđer Bošković. https://urn.nsk.hr/urn:nbn:hr:241:733364.

Tomić, D. 2021. Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein. Institut Ruđer Bošković. [Online]. [Accessed 17 July 2024]. Available from: https://urn.nsk.hr/urn:nbn:hr:241:733364.

Tomić D. Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein. [Internet]. Institut Ruđer Bošković: , HR; 2021, [cited 2024 July 17] Available from: https://urn.nsk.hr/urn:nbn:hr:241:733364.

D. Tomić, Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein, Institut Ruđer Bošković, 2021. Accessed on: Jul 17, 2024. Available: https://urn.nsk.hr/urn:nbn:hr:241:733364.